OTC · MICR
Micron Solutions, Inc.
$0.05$0.00 (0.0%)
Micron Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.2% below the high.
Loading market information…
OTC · MOTS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Motus GI Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.8% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Motus GI Holdings, Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$1.95. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Motus GI Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2022 | Mar 31, 2023 | -$11.84+36.82% vs estimate | $109.00K-72.05% vs estimate |
|---|
| Q3 2022 | Nov 14, 2022 | -$25.34+9.63% vs estimate | $278.00K-16.67% vs estimate |
|---|
| Q2 2022 | Aug 11, 2022 | -$27.89+10.98% vs estimate | $185.00K-7.5% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.05$0.00 (0.0%)
Micron Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.2% below the high.
$0.00$0.00 (0.0%)
Bionovate Technologies Corp: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
Adhera Therapeutics Inc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
CannAmerica Brands Corp.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
IMRIS Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.1% below the high.
$0.00$0.00 (0.0%)
Rosetta Genomics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
GlobeImmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.75% below the high.
$0.00$0.00 (0.0%)
Strategic Global Investments, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
